RxDoctor Payments Data

Carla Greenbaum

Endocrinology, Diabetes & Metabolism · Seattle, WANPI 1992880728

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,850 of the $7,481 with a category attached, or 78.2%. 3 manufacturers reported payments, led by AstraZeneca at 51.9% of the total.

$7,481in general payments, 2019–2025

Across 4 payments — averaging $1870.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Merck$4K
  • Pfizer$20
$2,576,346in research payments, 2019–2025

Across 119 payments — averaging $21,650 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$1.8M
  • E.r. Squibb & Sons, L.L.C.$672K
  • Sanofi US Services Inc.$73K
  • Janssen Research & Development, LLC$29K
  • Sanofi-aventis U.S. LLC$6K
  • Genentech, Inc.$6K

What the payments were for

  • Consulting fees$5,85078%
  • Speaking & faculty fees$1,61122%
  • Gifts$200%

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca2$3,886
Merck1$3,575
Pfizer1$20

How this compares

$7,481 in reported general payments places this provider in the 80th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.

See all endocrinology, diabetes & metabolism providers in Washington

Other endocrinology, diabetes & metabolism in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →